AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16053970
Drug: Ambrisentan 5
RxNorm normalized name: ambrisentan 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan 5 mg
Trial: 16053970
Drug: Ambrisentan 10
RxNorm normalized name: ambrisentan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan 10 mg
Trial: 16053970
Drug: Ambrisentan 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan 2.5 mg
Trial: 16805144
Drug: Acetazolamide 250
RxNorm normalized name: acetazolamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 250 mg daily
Trial: 1390316
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with carboplatin 400 mg/m2 day 1 and 5-FU 1 g/m2/d as a continuous infusion days 1 through 5 every 3 weeks, given to 108 patients.
Trial: 1390316
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy group (not specified as control).
Trial: 1390316
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (locoregional treatment alone).
Trial: 31120943
Drug: Influenza vaccination
RxNorm normalized name: Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine Injection [PedvaxHIB]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccination (inactivated quadrivalent influenza vaccine)
Trial: 26517576
Drug: Endoscopic variceal
RxNorm normalized name: VARICELLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic variceal ligation (EVL) + β-blocker
Trial: 24092275
Drug: CISTIMEV PLUS(®),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CISTIMEV PLUS(®), 1 tablet daily for 30 days
Trial: 16883904
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (BQG + sulfasalazine)
Trial: 7910472
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol 100 micrograms
Trial: 7910472
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol (cumulative doses of up to 400 micrograms)
Trial: 3540072
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase (1.5 million IU/h)
Trial: 24281606
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment on half of the wound surface
Trial: 24281606
Drug: No insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No insulin treatment on the other half of the wound surface
Trial: 17148968
Drug: Generic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic formulation of stavudine (40 mg twice daily)
Trial: 17148968
Drug: Generic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic formulation of lamivudine (150 mg twice daily)
Trial: 17148968
Drug: Generic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic formulation of nevirapine (200 mg twice daily)
Trial: 2701324
Drug: Behavioral Treatment
RxNorm normalized name: AspyreRx Digital Behavioral Therapeutic Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Treatment Program
Trial: 2701324
Drug: Methadone patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone patients receiving additional medication for cocaine dependence
Trial: 2701324
Drug: Inpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient treatment (28 days)
Trial: 2701324
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment (day hospital or behavioral treatment)
Trial: 302028
Drug: Isoprenaline inhalation
RxNorm normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoprenaline inhalation test
Trial: 23692260
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate or olmesartan medoxomil (antihypertensive treatment)
Trial: 21745623
Drug: BTE (333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTE (333 mg)
Trial: 16998649
Drug: Rivastigmine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (3 to 12 mg per day)
Trial: 11096003
Drug: Levofloxacin treatment
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin treatment
Trial: 11096003
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy (not specified)
Trial: 3304950
Drug: cyclandelate 800
RxNorm normalized name: Cyclandelate
DrugBank: Cyclandelate (DB04838)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclandelate 800 mg twice daily
Trial: 3304950
Drug: flunarizine 5
RxNorm normalized name: flunarizine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flunarizine 5 mg daily
Trial: 27823681
Drug: Prasugrel 5mg
RxNorm normalized name: Prasugrel 5mg Oral tablet
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prasugrel 5mg daily
Trial: 27823681
Drug: Clopidogrel 75mg
RxNorm normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel 75mg daily
Trial: 24602602
Drug: 5-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day course of amoxicillin/clavulanic acid 625 mg orally 8-hourly for 4 days after initial intravenous treatment
Trial: 24602602
Drug: 1-day course
RxNorm normalized name: ESTRADIOL BENZOATE 1 kg in 1 kg POWDER [Estradiol Benzoate Coarse Grade]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day course of amoxicillin/clavulanic acid 1.2g intravenously followed by placebo orally
Trial: 22828247
Drug: Inspiratory loads
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory loads (light: 8.4 cm H2O/L/s, moderate: 23.4 cm H2O/L/s, severe: 70.5 cm H2O/L/s) with deep breaths during normal breathing
Trial: 15942550
Drug: Oat bran
RxNorm normalized name: Oat bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat bran cereal containing beta glucan (3 g daily)
Trial: 10770343
Drug: Topical alitretinoin
RxNorm normalized name: alitretinoin Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical alitretinoin 0.1% gel
Trial: 10770343
Drug: Open-label alitretinoin
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label alitretinoin treatment after blinded phase
Trial: 8721798
Drug: Cholesterol-lowering treatments
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol-lowering treatments (specific types not detailed)
Trial: 8721798
Drug: Hormone treatments
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone treatments
Trial: 6139422
Drug: Luteinizing hormone
RxNorm normalized name: LUTEINIZING HORMONE
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone releasing hormone (LHRH)
Trial: 25121977
Drug: Antidepressant cessation
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressant cessation advice
Trial: 11208829
Drug: Denileukin diftitox
RxNorm normalized name: Denileukin diftitox
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Denileukin diftitox (both doses)
Trial: 3296163
Drug: Clindamycin and
RxNorm normalized name: clindamycin and benzoyl peroxide KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin and gentamicin (C + G)
Trial: 24766166
Drug: Weekly telephone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly telephone calls
Trial: 19010769
Drug: Intratumoural chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoural chemotherapy
Trial: 16160615
Drug: Olanzapine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10 mg/d, mean dose at endpoint 8.75 mg/day)
Trial: 16160615
Drug: Risperidone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (4 mg/d, mean dose at endpoint 2.88 mg/d)
Trial: 12893107
Drug: Short-term treatment
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term treatment of depression in patients with diabetes
Trial: 12893107
Drug: Psychotherapy and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy and/or psychopharmacologic treatment
Trial: 8857250
Drug: Chemiluminescent immunoassay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemiluminescent immunoassay (CLIA) for thyroid stimulating hormone (TSH) and free-T4
Trial: 8857250
Drug: Chemiluminescent immunoassay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemiluminescent immunoassay (CLIA) for intact-parathyroid hormone (PTH)
Trial: 1825315
Drug: HIV-1-infected persons
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HIV-1-infected persons who received vaccine doses at the time of new HBV infection
Trial: 6395212
Drug: Adjuvant cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant cyclophosphamide, vincristine, prednisone (CVP) chemotherapy with extended field radiotherapy (RT) in stage I patients.
Trial: 25315941
Drug: Icy normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icy normal saline group (1,000 mL of 4°C normal saline intravenously)
Trial: 22305917
Drug: 400-mcg buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400-mcg buccal misoprostol
Trial: 22305917
Drug: 800-mcg buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800-mcg buccal misoprostol
Trial: 15691349
Drug: Ibuprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (200 mg tablets, twice daily)
Trial: 10652038
Drug: Potassium-magnesium citrate
RxNorm normalized name: potassium magnesium aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium-magnesium citrate (KMgCit; 42 mEq K, 21 mEq Mg, and 63 mEq citrate/day)
Trial: 1944425
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of oral milrinone daily
Trial: 26346122
Drug: Protocol B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol B (hyaluronic acid injection + low-level laser therapy)
Trial: 26346122
Drug: Protocol A
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol A (sham light source + saline injection)
Trial: 23707331
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa (NS) 500 mg capsule twice daily for nine weeks
Trial: 21912062
Drug: Albendazole therapy
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole therapy for 12 weeks preoperatively and 12 weeks postoperatively
Trial: 21912062
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative albendazole therapy (control group)
Trial: 12945071
Drug: Cox-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cox-2 inhibitors
Trial: 31207169
Drug: Fasinumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasinumab (1 mg, 3 mg, 6 mg, or 9 mg) every 4 weeks for 16 weeks
Trial: 31207169
Drug: Fasinumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasinumab (6 mg)
Trial: 29944580
Drug: Carnoy's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnoy's solution
Trial: 29944580
Drug: Revision group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revision group (formalin specimens immersed in Carnoy's solution)
Trial: 20678893
Drug: Heated patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heated patch (lidocaine 70 mg/tetracaine 70 mg)
Trial: 20678893
Drug: Unheated patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unheated patch (lidocaine 70 mg/tetracaine 70 mg)
Trial: 15844579
Drug: BCG‐SPN intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG‐SPN intramuscular injection (1ml, once every two days for 5 weeks)
Trial: 15844579
Drug: Corticosteroid nasal
RxNorm normalized name: Corticosteroid nasal preparations for topical use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid nasal spray (once a day for 5 weeks)
Trial: 15844579
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of BCG‐SPN and corticosteroid nasal spray (as above for 5 weeks)
Trial: 12460131
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment approaches (5 types)
Trial: 12460131
Drug: Outpatient drug-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient drug-free programs for adults (previous DATCAP results)
Trial: 9799979
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg mepivacaine 4% only
Trial: 358713
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin (5000 U) administered 2 hours before surgery and every 8 hours for 6 days.
Trial: 358713
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections administered to 47 operated patients.
Trial: 25034442
Drug: Oleogel-S10 ointment
RxNorm normalized name: Oleogel-S10
DrugBank: Birch bark extract (DB16536)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oleogel-S10 ointment containing 10% birch bark extract
Trial: 17348463
Drug: Clopidogrel (as
RxNorm normalized name: Clopidogrel (as clopidogrel besilate) 75 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (as a second antiplatelet drug)
Trial: 17348463
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy without clopidogrel
Trial: 11771654
Drug: Raloxifene (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (any dose)
Trial: 9829138
Drug: 11-visit treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 11-visit treatment program
Trial: 9802368
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (2 mg/kg)
Trial: 8135557
Drug: Salbutamol (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (0.15 mg/kg every 30 minutes for the first three hours)
Trial: 8135557
Drug: Salbutamol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (5 mg every one to four hours as needed)
Trial: 23727002
Drug: HBsAg-1018 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBsAg-1018 (2 doses at 0 and 4 weeks)
Trial: 23727002
Drug: HBsAg-Eng (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBsAg-Eng (3 doses at 0, 4, and 24 weeks)
Trial: 9576383
Drug: DTaP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP plus oral polio vaccine (OPV)
Trial: 9576383
Drug: DTaP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP plus eIPV (separate injections)
Trial: 9576383
Drug: DTaP-eIPV combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-eIPV combined as a single injection
Trial: 9576383
Drug: DTaP-eIPV combined,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-eIPV combined, plus a separate injection of PRP-T
Trial: 9576383
Drug: DTaP-eIPV combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-eIPV combined and reconstituting PRP-T, as a single injection
Trial: 9576383
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of DTaP reconstituting PRP-T as a single injection
Trial: 1978163
Drug: Salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 micrograms inhaled before allergen challenge
Trial: 31856741
Drug: Impaired kidney
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impaired kidney function (eGFR < 60 ml/min/1.73m²)
Trial: 31856741
Drug: Mildly impaired
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mildly impaired kidney function (eGFR 45-<60 ml/min/1.73m²)
Trial: 28535809
Drug: Rosiglitazone (0.045
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (0.045 mg/kg/dose) twice daily for 4 days
Trial: 25979561
Drug: 500 cc
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 cc Saline by rectal enema
Trial: 25979561
Drug: six bisacodyl
RxNorm normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: six bisacodyl tablets
Trial: 23490325
Drug: Epimacular brachytherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epimacular brachytherapy (EMBT) with 2 mandated monthly ranibizumab injections followed by pro re nata (PRN) ranibizumab
Trial: 23490325
Drug: 3 mandated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mandated monthly ranibizumab injections followed by mandated quarterly plus PRN ranibizumab
Trial: 16937963
Drug: Ribose (625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribose (625 mg)
Trial: 15309425
Drug: Transdermal progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal progesterone (TPD+)
Trial: 15309425
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of soy+ and TPD+
Trial: 15309425
Drug: Placebo (isoflavone-poor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (isoflavone-poor soymilk and progesterone-free cream)
Trial: 20199137
Drug: Liraglutide (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (0.9 mg once daily)
Trial: 20199137
Drug: Glibenclamide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (2.5 mg/day, once or twice daily)
Trial: 15639169
Drug: 21-mg transdermal
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 21-mg transdermal nicotine patch (smokers)
Trial: 15639169
Drug: 7-mg transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-mg transdermal nicotine patch (nonsmokers)
Trial: 12860725
Drug: Chemokine antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Chemokine antagonist
Trial: 1997083
Drug: Bupivacaine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (40 ml of 0.25%)
Trial: 1997083
Drug: Saline (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (40 ml)
Trial: 6392105
Drug: Intravenous acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acyclovir (30 mg/kg per day for five days)
Trial: 31122212
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate plus prednisone (AAP) and Androgen Deprivation Therapy (ADT)
Trial: 31122212
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of AAP (without ADT) and apalutamide
Trial: 29789507
Drug: Caffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated coffee (CAF) consumption (5.5 mg/kg of caffeine)
Trial: 24981585
Drug: Endovenous steam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovenous steam ablation (EVSA) high dose
Trial: 19237660
Drug: Salsalate (4500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salsalate (4500 mg/d)
Trial: 12234030
Drug: Direct anterior
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct anterior electron field treatment
Trial: 12234030
Drug: Tangential photon
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tangential photon treatment
Trial: 9620901
Drug: Intranasal cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal cold dry air (CDA)
Trial: 7988978
Drug: Cefotaxime i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime i.v. followed by Cefixime oral (2 x 2 g cefotaxime i.v. for 7 to 10 days, then 1 x 400 mg cefixime for 5 to 8 days)
Trial: 7988978
Drug: Cefotaxime parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime parenteral (2 x 2 g cefotaxime for 48 to 72 hours)
Trial: 7988978
Drug: Cefotaxime i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime i.v. followed by Cefixime oral
Trial: 7988978
Drug: Cefotaxime parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime parenteral